CLOSURE Medical Appoints Three New Vice Presidents
January 06 2004 - 1:23PM
PR Newswire (US)
CLOSURE Medical Appoints Three New Vice Presidents RALEIGH, N.C.,
Jan. 6 /PRNewswire-FirstCall/ -- CLOSURE Medical Corporation , a
global leader in biomaterial-based medical devices, announced today
the appointment of three new vice presidents effective immediately.
CLOSURE President and CEO, Daniel A. Pelak, commented, "During
2003, CLOSURE made significant progress growing its revenue and
profitability while at the same time broadening its product
offerings. Simultaneously, we have been executing a strategic plan
that requires the continued development of multiple products and
expansion into new markets, which is a major departure from the
single product orientation in CLOSURE's past. As a part of this
plan, we have expanded our management team and realigned our
organization with a view towards achieving our strategic
objectives." A six-year veteran at CLOSURE, J. Michael Hoban, 52,
was appointed to the new position of Vice President of Human
Resources. Prior to his appointment, Mr. Hoban served as CLOSURE's
Director of Human Resources. Before joining the Company, Mr. Hoban
spent twenty years with Bristol-Myers Squibb Inc. serving in a
variety of human resource roles; his last position there was Vice
President of Human Resources for the Zimmer Surgical Products
Division. He holds a B.A. in Labor and Industrial Relations from
Michigan State University. Bruce J. Krattenmaker, 51, has been
appointed as Vice President of Regulatory, Clinical and Quality
Assurance. Mr. Krattenmaker has over twenty years of experience
within the quality assurance and regulatory field. Most recently,
Mr. Krattenmaker served as Vice President of Regulatory Affairs,
Quality Assurance and Clinical Programs at Ev3 Inc., based in
Plymouth, Minnesota, where he was responsible for developing and
executing regulatory strategies on a global basis. He also held
various executive positions at Boston Scientific Corporation, C.R.
Bard, Inc. and Baxter Healthcare Corporation. Mr. Krattenmaker has
a B.S. in Biology and an M.S. in Microbiology and Biochemistry,
each from Northern Illinois University. Gabe N. Szabo, 40, has been
appointed to Vice President of New Product Development. Previously,
Mr. Szabo was Director of Marketing for CLOSURE's consumer care
products. Prior to joining the Company in 1999, Mr. Szabo worked
for both Johnson & Johnson and General Electric Company in
various management, product development, and engineering roles. Mr.
Szabo holds a B.S. in Mechanical Engineering from Northeastern
University and an M.B.A. from Duke University's Fuqua School of
Business. Mr. Pelak said, "We are very pleased to expand the
executive management team with top-tier, experienced individuals
during this time in our Company's evolution. I believe the
leadership team we have assembled at CLOSURE is well-suited to lead
this organization to the next level and I am truly privileged to be
working with each of them." About CLOSURE Medical Corporation
CLOSURE Medical Corporation is a global leader in the development
and manufacture of innovative biomaterial-based medical devices
that fulfill the needs of healthcare practitioners, patients and
consumers. For additional information on CLOSURE Medical visit its
website at http://www.closuremed.com/ or visit the "Clients"
section of the Allen & Caron website at
http://www.allencaron.com/ . This release contains certain
forward-looking statements which involve known and unknown risks,
delays, uncertainties or other factors not under the Company's
control which may cause actual results, performance or achievements
of the Company to be materially different from the results,
performance, or other expectations implied by these forward-looking
statements. These factors include, but are not limited to the early
stage of commercialization of the Company's products; the progress
of its research and development programs for future products; the
need for regulatory approval and effects of governmental
regulation; technological uncertainties; the satisfactory
conclusion of negotiations with, and dependence on marketing
partners, and dependence on patents and trade secrets, as well as
those detailed in the Company's Annual Report on Form 10-K for the
year ended December 31, 2002, filed with the Securities and
Exchange Commission. Although the Company believes that the
expectations in the forward-looking statements are reasonable, the
Company cannot guarantee such results. The Company undertakes no
obligation to publicly revise these forward-looking statements to
reflect events or circumstances that arise after the date hereof.
DATASOURCE: CLOSURE Medical Corporation CONTACT: investors, Joe
Allen, +1-212-691-8087, , or media, Len Hall, +1-949-474-4300, ,
both of Allen & Caron Inc, for CLOSURE Medical Corporation; or
Benny Ward, CFO of CLOSURE Medical Corporation, +1-919-876-7800 Web
site: http://www.allencaron.com/ Web site:
http://www.closuremed.com/
Copyright
Closure Medical (NASDAQ:CLSR)
Historical Stock Chart
From Apr 2024 to May 2024
Closure Medical (NASDAQ:CLSR)
Historical Stock Chart
From May 2023 to May 2024